Osteoarthritis Therapeutics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The osteoarthritis therapeutics market was valued at USD 9.13 Billion in 2024 driven by the rising prevalence of osteoarthritis across the 8 major markets. The market size is anticipated to grow at a CAGR of 8.70% during the forecast period of 2025-2034 to achieve a value of USD 21.03 Billion by 2034.
Osteoarthritis Therapeutics Market Overview
Millions of people are suffering from osteoarthritis, which is the most prevalent kind of arthritis. It happens due to damage to the protective cartilage that cushions the ends of the bones. Even though osteoarthritis can harm any joint, it frequently affects the hands, knees, hips, and spine. While the damage to joints cannot be undone, osteoarthritis symptoms can typically be controlled. The progression of the disease may be slowed down, and pain and joint function may be improved by staying active, maintaining a healthy weight, and taking specific therapies.
The increasing aging population that is more prone to developing chronic joint conditions is driving the growth of the osteoarthritis therapeutics market. The growing initiatives of investments from both private and government organizations are also favoring market expansion. Moreover, the rising demand for effective pain management therapies, increasing preference for regenerative medicine, and growing public awareness are poised to impact the market dynamics significantly.
Osteoarthritis Therapeutics Market Growth Drivers
Increasing Elderly Population to Fuel Market Growth
The growing geriatric population is a major factor influencing the market growth. It can be attributed to the high prevalence of bone-related conditions in older adults. It is common in older people to develop joint issues such as joint pain and discomfort while walking or exercising. The chances of developing osteoarthritis in women are more in comparison to men after the age of 50. According to WHO, 1 in every 6 people worldwide will be aged 60 years or above by 2030. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). Moreover, the number of individuals aged 80 years or older is expected to triple between 2020 and 2050 and is projected to reach 426 million. This data indicates that a rise in osteoarthritis cases is expected in the coming years which will directly contribute to the market growth.
Osteoarthritis Therapeutics Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Robust Regulatory Support to Affect the Market Landscape Significantly
In September 2024 , pharma company Sun Pharmaceutical Industries and clinical-stage biotech company Moebius Medical announced that their non-opioid treatment MM-II (Large Liposomes of DPPC [dipalmitoylphosphatidylcholine] and DMPC [1,2‐dimyristoyl‐sn‐glycero‐3‐phosphocholine]) has received fast track designation from the US Food and Drug Administration (FDA) for osteoarthritis knee pain. Such regulatory support is anticipated to propel market growth in the forecast period.
Launch of Innovative Products Poised to Augment Osteoarthritis Therapeutics Market Demand
The key players in the market are focused on launching new and effective products to address osteoarthritis discomfort in patients, which also contributes to the market growth. For instance, the FDA approved the MISHA Knee System, which is an implantable shock absorber effective in partially reducing the load on the knee joint. This load reduction is expected to result in reduced pain and preserve the functionality of the knee. This device can be implanted subcutaneously during an outpatient-compatible procedure.
Growth in Clinical Trials Set to Elevate the Osteoarthritis Therapeutics Market Value
There have been multiple research studies going on to develop new effective drugs for the treatment of osteoarthritis, which is set to elevate the market value. For example, the researchers at the Keck School of Medicine of USC (University of Southern California) launched a combined safety and preliminary efficacy clinical trial (Phases I and IIa) of R805/CX-011 for the treatment of osteoarthritis. This clinical trial was followed by their previously successful animal-based trial which was performed on a rat and was concluded to be effective. The new treatment is expected to provide a less expensive alternative, also a less invasive option, which would be easy to administer several times a year, with a high potential of delaying or even reducing the need for surgical procedures.
Increased Focus on Biologic Therapies Likely to Boost Osteoarthritis Therapeutics Market Size
One of the major market trends is the growing emphasis on the development of biologics such as monoclonal antibodies and cell-based therapies. Biologic therapies are known to target specific molecules involved in the inflammation and degradation of joint tissues and thus can potentially offer better efficacy and fewer side effects compared to traditional drugs.
Osteoarthritis Therapeutics Market Segmentation
"Osteoarthritis Therapeutics Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Segmentation Based on Drug Class is Anticipated to Witness Substantial Growth
Based on the drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), other analgesics, corticosteroids, hyaluronic acid injections, and others. NSAIDs cover a major market share owing to their efficacy in reducing pain and inflammation. For managing mild to moderate cases of osteoarthritis, medications like ibuprofen and naproxen are commonly used by the patients. However, long-term use of NSAIDs is linked to gastrointestinal and cardiovascular side effects.
Osteoarthritis Therapeutics Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is one of the leading markets for osteoarthritis therapeutics due to the high prevalence of the condition, a substantial aging population, and significant R&D investment. The availability of advanced biologic therapies, including TNF inhibitors, JAK inhibitors, and hyaluronic acid injections, also supports the growth of the market in the region. Moreover, the rising interest in stem cell therapy and platelet-rich plasma (PRP) treatments is likely to impact the market dynamics in the country.
Leading Players in the Osteoarthritis Therapeutics Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Sanofi
This French multinational pharmaceutical and healthcare company is one of the dominant players in the market for osteoarthritis treatments. The company offers a robust portfolio of nonsteroidal anti-inflammatory drugs (NSAIDs) and pain management products.
Bayer AG
Bayer, headquartered in Leverkusen, Germany, is a leading pharmaceutical and biotechnology company. Bayer is focused on developing new formulations of pain relief medications that can be used to treat osteoarthritis symptoms.
Haleon plc
British multinational consumer healthcare company Haleon is a significant player in the market, particularly in the over-the-counter (OTC) segment of the osteoarthritis treatment space. It offers a wide range of pain relief products and is actively investing in developing more advanced, long-acting topical treatments for osteoarthritis patients.
Seikagaku Corporation
Japan-based Seikagaku Corporation specializes in the development and manufacturing of hyaluronic acid-based therapies, which are commonly used by knee osteoarthritis patients. The company is focused on collaborating with international partners to expand its global presence.
Other key players in the market include Bristol Myers Squibb, Ono Pharmaceutical, Novartis AG, Pfizer Inc., Assertio Holdings, Pacira Biosciences Inc., Anika Therapeutics Inc., and Bioventus LLC.
Key Questions Answered in the Osteoarthritis Therapeutics Market Report
Osteoarthritis Therapeutics Market Overview
Millions of people are suffering from osteoarthritis, which is the most prevalent kind of arthritis. It happens due to damage to the protective cartilage that cushions the ends of the bones. Even though osteoarthritis can harm any joint, it frequently affects the hands, knees, hips, and spine. While the damage to joints cannot be undone, osteoarthritis symptoms can typically be controlled. The progression of the disease may be slowed down, and pain and joint function may be improved by staying active, maintaining a healthy weight, and taking specific therapies.
The increasing aging population that is more prone to developing chronic joint conditions is driving the growth of the osteoarthritis therapeutics market. The growing initiatives of investments from both private and government organizations are also favoring market expansion. Moreover, the rising demand for effective pain management therapies, increasing preference for regenerative medicine, and growing public awareness are poised to impact the market dynamics significantly.
Osteoarthritis Therapeutics Market Growth Drivers
Increasing Elderly Population to Fuel Market Growth
The growing geriatric population is a major factor influencing the market growth. It can be attributed to the high prevalence of bone-related conditions in older adults. It is common in older people to develop joint issues such as joint pain and discomfort while walking or exercising. The chances of developing osteoarthritis in women are more in comparison to men after the age of 50. According to WHO, 1 in every 6 people worldwide will be aged 60 years or above by 2030. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). Moreover, the number of individuals aged 80 years or older is expected to triple between 2020 and 2050 and is projected to reach 426 million. This data indicates that a rise in osteoarthritis cases is expected in the coming years which will directly contribute to the market growth.
Osteoarthritis Therapeutics Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Robust Regulatory Support to Affect the Market Landscape Significantly
In September 2024 , pharma company Sun Pharmaceutical Industries and clinical-stage biotech company Moebius Medical announced that their non-opioid treatment MM-II (Large Liposomes of DPPC [dipalmitoylphosphatidylcholine] and DMPC [1,2‐dimyristoyl‐sn‐glycero‐3‐phosphocholine]) has received fast track designation from the US Food and Drug Administration (FDA) for osteoarthritis knee pain. Such regulatory support is anticipated to propel market growth in the forecast period.
Launch of Innovative Products Poised to Augment Osteoarthritis Therapeutics Market Demand
The key players in the market are focused on launching new and effective products to address osteoarthritis discomfort in patients, which also contributes to the market growth. For instance, the FDA approved the MISHA Knee System, which is an implantable shock absorber effective in partially reducing the load on the knee joint. This load reduction is expected to result in reduced pain and preserve the functionality of the knee. This device can be implanted subcutaneously during an outpatient-compatible procedure.
Growth in Clinical Trials Set to Elevate the Osteoarthritis Therapeutics Market Value
There have been multiple research studies going on to develop new effective drugs for the treatment of osteoarthritis, which is set to elevate the market value. For example, the researchers at the Keck School of Medicine of USC (University of Southern California) launched a combined safety and preliminary efficacy clinical trial (Phases I and IIa) of R805/CX-011 for the treatment of osteoarthritis. This clinical trial was followed by their previously successful animal-based trial which was performed on a rat and was concluded to be effective. The new treatment is expected to provide a less expensive alternative, also a less invasive option, which would be easy to administer several times a year, with a high potential of delaying or even reducing the need for surgical procedures.
Increased Focus on Biologic Therapies Likely to Boost Osteoarthritis Therapeutics Market Size
One of the major market trends is the growing emphasis on the development of biologics such as monoclonal antibodies and cell-based therapies. Biologic therapies are known to target specific molecules involved in the inflammation and degradation of joint tissues and thus can potentially offer better efficacy and fewer side effects compared to traditional drugs.
Osteoarthritis Therapeutics Market Segmentation
"Osteoarthritis Therapeutics Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Hip Osteoarthritis
- Spinal Osteoarthritis
- Knee Osteoarthritis
- Hand Osteoarthritis
- Others
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Other Analgesics
- Corticosteroids
- Hyaluronic Acid Injections
- Others
- Tablets and Capsules
- Injections
- Creams and Gels
- Others
- Oral
- Parenteral
- Topical
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Drug Class is Anticipated to Witness Substantial Growth
Based on the drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), other analgesics, corticosteroids, hyaluronic acid injections, and others. NSAIDs cover a major market share owing to their efficacy in reducing pain and inflammation. For managing mild to moderate cases of osteoarthritis, medications like ibuprofen and naproxen are commonly used by the patients. However, long-term use of NSAIDs is linked to gastrointestinal and cardiovascular side effects.
Osteoarthritis Therapeutics Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is one of the leading markets for osteoarthritis therapeutics due to the high prevalence of the condition, a substantial aging population, and significant R&D investment. The availability of advanced biologic therapies, including TNF inhibitors, JAK inhibitors, and hyaluronic acid injections, also supports the growth of the market in the region. Moreover, the rising interest in stem cell therapy and platelet-rich plasma (PRP) treatments is likely to impact the market dynamics in the country.
Leading Players in the Osteoarthritis Therapeutics Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Sanofi
This French multinational pharmaceutical and healthcare company is one of the dominant players in the market for osteoarthritis treatments. The company offers a robust portfolio of nonsteroidal anti-inflammatory drugs (NSAIDs) and pain management products.
Bayer AG
Bayer, headquartered in Leverkusen, Germany, is a leading pharmaceutical and biotechnology company. Bayer is focused on developing new formulations of pain relief medications that can be used to treat osteoarthritis symptoms.
Haleon plc
British multinational consumer healthcare company Haleon is a significant player in the market, particularly in the over-the-counter (OTC) segment of the osteoarthritis treatment space. It offers a wide range of pain relief products and is actively investing in developing more advanced, long-acting topical treatments for osteoarthritis patients.
Seikagaku Corporation
Japan-based Seikagaku Corporation specializes in the development and manufacturing of hyaluronic acid-based therapies, which are commonly used by knee osteoarthritis patients. The company is focused on collaborating with international partners to expand its global presence.
Other key players in the market include Bristol Myers Squibb, Ono Pharmaceutical, Novartis AG, Pfizer Inc., Assertio Holdings, Pacira Biosciences Inc., Anika Therapeutics Inc., and Bioventus LLC.
Key Questions Answered in the Osteoarthritis Therapeutics Market Report
- What was the osteoarthritis therapeutics market value in 2023?
- What is the osteoarthritis therapeutics market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on type?
- What is the market breakup based on drug class?
- What is the market breakup by dosage form?
- What is the market breakup by the route of administration?
- What are the major end users of the market?
- What are the major distribution channels of the market?
- What are the major factors aiding the osteoarthritis therapeutics market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of osteoarthritis affect the market landscape?
- What are the major osteoarthritis therapeutics market trends?
- How does the rise in the geriatric population impact the market size?
- Which osteoarthritis therapeutics type will dominate the market share?
- Which drug class is expected to have a high market value in the coming years?
- Which dose form will experience the highest demand in the market segment?
- Which route of administration holds a high market value?
- Which end user is projected to contribute to the highest market growth?
- Which distribution channel dominates the market share?
- Who are the key players involved in the osteoarthritis therapeutics market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Osteoarthritis Therapeutics Market Overview – 8 Major Markets
- 3.1 Osteoarthritis Therapeutics Market Historical Value (2018-2024)
- 3.2 Osteoarthritis Therapeutics Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Osteoarthritis Therapeutics Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Osteoarthritis Therapeutics Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU-4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 U.S.
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU-4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment seeking rate, by Country
- 7.1.3.1 U.S.
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU-4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Osteoarthritis Therapeutics Market Landscape – 8 Major Markets
- 8.1 Osteoarthritis Therapeutics: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Osteoarthritis Therapeutics: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Drug Class
- 8.2.3 Analysis by Route of Administration
- 8.2.4 Analysis by Doses form
- 9 Osteoarthritis Therapeutics Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Osteoarthritis Therapeutics Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Osteoarthritis Therapeutics Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Osteoarthritis Therapeutics Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Hip Osteoarthritis
- 12.1.3 Spinal Osteoarthritis
- 12.1.4 Knee Osteoarthritis
- 12.1.5 Hand Osteoarthritis
- 12.1.6 Others
- 12.2 Osteoarthritis Therapeutics Market (2018-2034) by Drug Class
- 12.2.1 Market Overview
- 12.2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 12.2.3 Other Analgesics
- 12.2.4 Corticosteroids
- 12.2.5 Hyaluronic Acid Injections
- 12.2.6 Others
- 12.3 Osteoarthritis Therapeutics Market (2018-2034) by Doses Form
- 12.3.1 Market Overview
- 12.3.2 Tablets and Capsules
- 12.3.3 Injections
- 12.3.4 Creams and Gels
- 12.3.5 Others
- 12.4 Osteoarthritis Therapeutics Market (2018-2034) by Route of Administration
- 12.4.1 Market Overview
- 12.4.2 Oral
- 12.4.3 Parenteral
- 12.4.4 Topical
- 12.5 Osteoarthritis Therapeutics Market (2018-2034) by End User
- 12.5.1 Market Overview
- 12.5.2 Hospitals
- 12.5.3 Specialty Clinics
- 12.5.4 Homecare Settings
- 12.5.5 Others
- 12.6 Osteoarthritis Therapeutics Market (2018-2034) by Distribution Channel
- 12.6.1 Market Overview
- 12.6.2 Hospital Pharmacies
- 12.6.3 Retail Pharmacies
- 12.6.4 Online Pharmacies
- 12.6.5 Others
- 12.7 Osteoarthritis Therapeutics Market (2018-2034) by Region
- 12.7.1 Market Overview
- 12.7.2 United States
- 12.7.3 EU-4 and the United Kingdom
- 12.7.3.1 Germany
- 12.7.3.2 France
- 12.7.3.3 Italy
- 12.7.3.4 Spain
- 12.7.3.5 United Kingdom
- 12.7.4 India
- 12.7.5 Japan
- 13 United States Osteoarthritis Therapeutics Market (218-2034)
- 13.1 United States Osteoarthritis Therapeutics Market Historical Value (2018-2024)
- 13.2 United States Osteoarthritis Therapeutics Market Forecast Value (2025-2034)
- 13.3 United States Osteoarthritis Therapeutics Market (2018-2034) by Type
- 13.3.1 Market Overview
- 13.3.2 Hip Osteoarthritis
- 13.3.3 Spinal Osteoarthritis
- 13.3.4 Knee Osteoarthritis
- 13.3.5 Hand Osteoarthritis
- 13.3.6 Others
- 13.4 United States Osteoarthritis Therapeutics Market (2018-2034) by Drug Class
- 13.4.1 Market Overview
- 13.4.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 13.4.3 Other Analgesics
- 13.4.4 Corticosteroids
- 13.4.5 Hyaluronic Acid Injections
- 13.4.6 Others
- 13.5 United States Osteoarthritis Therapeutics Market (2018-2034) by Doses Form
- 13.5.1 Market Overview
- 13.5.2 Tablets and Capsules
- 13.5.3 Injections
- 13.5.4 Creams and Gels
- 13.5.5 Others
- 13.6 United States Osteoarthritis Therapeutics Market (2018-2034) by Route of Administration
- 13.6.1 Market Overview
- 13.6.2 Oral
- 13.6.3 Parenteral
- 13.6.4 Topical
- 13.7 United States Osteoarthritis Therapeutics Market (2018-2034) by End User
- 13.7.1 Market Overview
- 13.7.2 Hospitals
- 13.7.3 Specialty Clinics
- 13.7.4 Homecare Settings
- 13.7.5 Others
- 13.8 United States Osteoarthritis Therapeutics Market (2018-2034) by Distribution Channel
- 13.8.1 Market Overview
- 13.8.2 Hospital Pharmacies
- 13.8.3 Retail Pharmacies
- 13.8.4 Online Pharmacies
- 13.8.5 Others
- 14 EU-4 and United Kingdom Osteoarthritis Therapeutics Market (218-2034)
- 14.1 EU-4 and United Kingdom Osteoarthritis Therapeutics Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Osteoarthritis Therapeutics Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Osteoarthritis Therapeutics Market (2018-2034) by Type
- 14.3.1 Market Overview
- 14.3.2 Hip Osteoarthritis
- 14.3.3 Spinal Osteoarthritis
- 14.3.4 Knee Osteoarthritis
- 14.3.5 Hand Osteoarthritis
- 14.3.6 Others
- 14.4 EU-4 and United Kingdom Osteoarthritis Therapeutics Market (2018-2034) by Drug Class
- 14.4.1 Market Overview
- 14.4.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 14.4.3 Other Analgesics
- 14.4.4 Corticosteroids
- 14.4.5 Hyaluronic Acid Injections
- 14.4.6 Others
- 14.5 EU-4 and United Kingdom Osteoarthritis Therapeutics Market (2018-2034) by Doses Form
- 14.5.1 Market Overview
- 14.5.2 Tablets and Capsules
- 14.5.3 Injections
- 14.5.4 Creams and Gels
- 14.5.5 Others
- 14.6 EU-4 and United Kingdom Osteoarthritis Therapeutics Market (2018-2034) by Route of Administration
- 14.6.1 Market Overview
- 14.6.2 Oral
- 14.6.3 Parenteral
- 14.6.4 Topical
- 14.7 EU-4 and United Kingdom Osteoarthritis Therapeutics Market (2018-2034) by End User
- 14.7.1 Market Overview
- 14.7.2 Hospitals
- 14.7.3 Specialty Clinics
- 14.7.4 Homecare Settings
- 14.7.5 Others
- 14.8 EU-4 and United Kingdom Osteoarthritis Therapeutics Market (2018-2034) by Distribution Channel
- 14.8.1 Market Overview
- 14.8.2 Hospital Pharmacies
- 14.8.3 Retail Pharmacies
- 14.8.4 Online Pharmacies
- 14.8.5 Others
- 15 India Osteoarthritis Therapeutics Market
- 15.1 India Osteoarthritis Therapeutics Market Historical Value (2018-2024)
- 15.2 India Osteoarthritis Therapeutics Market Forecast Value (2025-2034)
- 15.3 India Osteoarthritis Therapeutics Market (2018-2034) by Type
- 15.3.1 Market Overview
- 15.3.2 Hip Osteoarthritis
- 15.3.3 Spinal Osteoarthritis
- 15.3.4 Knee Osteoarthritis
- 15.3.5 Hand Osteoarthritis
- 15.3.6 Others
- 15.4 India Osteoarthritis Therapeutics Market (2018-2034) by Drug Class
- 15.4.1 Market Overview
- 15.4.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 15.4.3 Other Analgesics
- 15.4.4 Corticosteroids
- 15.4.5 Hyaluronic Acid Injections
- 15.4.6 Others
- 15.5 India Osteoarthritis Therapeutics Market (2018-2034) by Doses Form
- 15.5.1 Market Overview
- 15.5.2 Tablets and Capsules
- 15.5.3 Injections
- 15.5.4 Creams and Gels
- 15.5.5 Others
- 15.6 India Osteoarthritis Therapeutics Market (2018-2034) by Route of Administration
- 15.6.1 Market Overview
- 15.6.2 Oral
- 15.6.3 Parenteral
- 15.6.4 Topical
- 15.7 India Osteoarthritis Therapeutics Market (2018-2034) by End User
- 15.7.1 Market Overview
- 15.7.2 Hospitals
- 15.7.3 Specialty Clinics
- 15.7.4 Homecare Settings
- 15.7.5 Others
- 15.8 India Osteoarthritis Therapeutics Market (2018-2034) by Distribution Channel
- 15.8.1 Market Overview
- 15.8.2 Hospital Pharmacies
- 15.8.3 Retail Pharmacies
- 15.8.4 Online Pharmacies
- 15.8.5 Others
- 16 Japan Osteoarthritis Therapeutics Market
- 16.1 Japan Osteoarthritis Therapeutics Market Historical Value (2018-2024)
- 16.2 Japan Osteoarthritis Therapeutics Market Forecast Value (2025-2034)
- 16.3 Japan Osteoarthritis Therapeutics Market (2018-2034) by Type
- 16.3.1 Market Overview
- 16.3.2 Hip Osteoarthritis
- 16.3.3 Spinal Osteoarthritis
- 16.3.4 Knee Osteoarthritis
- 16.3.5 Hand Osteoarthritis
- 16.3.6 Others
- 16.4 Japan Osteoarthritis Therapeutics Market (2018-2034) by Drug Class
- 16.4.1 Market Overview
- 16.4.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 16.4.3 Other Analgesics
- 16.4.4 Corticosteroids
- 16.4.5 Hyaluronic Acid Injections
- 16.4.6 Others
- 16.5 Japan Osteoarthritis Therapeutics Market (2018-2034) by Doses Form
- 16.5.1 Market Overview
- 16.5.2 Tablets and Capsules
- 16.5.3 Injections
- 16.5.4 Creams and Gels
- 16.5.5 Others
- 16.6 Japan Osteoarthritis Therapeutics Market (2018-2034) by Route of Administration
- 16.6.1 Market Overview
- 16.6.2 Oral
- 16.6.3 Parenteral
- 16.6.4 Topical
- 16.7 Japan Osteoarthritis Therapeutics Market (2018-2034) by End User
- 16.7.1 Market Overview
- 16.7.2 Hospitals
- 16.7.3 Specialty Clinics
- 16.7.4 Homecare Settings
- 16.7.5 Others
- 16.8 Japan Osteoarthritis Therapeutics Market (2018-2034) by Distribution Channel
- 16.8.1 Market Overview
- 16.8.2 Hospital Pharmacies
- 16.8.3 Retail Pharmacies
- 16.8.4 Online Pharmacies
- 16.8.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.1.1 US FDA
- 17.1.2 EU EMA
- 17.1.3 Japan PMDA
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Grants Analysis
- 19.1 Analysis by Year
- 19.2 Analysis by Amount Awarded
- 19.3 Analysis by Issuing Authority
- 19.4 Analysis by Grant Application
- 19.5 Analysis by Funding Institute
- 19.6 Analysis by NIH Departments
- 19.7 Analysis by Recipient Organization
- 20 Clinical Trials Analysis
- 20.1 Analysis by Trial Registration Year
- 20.2 Analysis by Trial Status
- 20.3 Analysis by Trial Phase
- 20.4 Analysis by Therapeutic Area
- 20.5 Analysis by Geography
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Sanofi
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Development
- 23.2.5 Certifications
- 23.3 Bayer AG
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Development
- 23.3.5 Certifications
- 23.4 Haleon plc
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Development
- 23.4.5 Certifications
- 23.5 Seikagaku Corporation
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Development
- 23.5.5 Certifications
- 23.6 Bristol Myers Squibb
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Development
- 23.6.5 Certifications
- 23.7 Ono Pharmaceutical
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Development
- 23.7.5 Certifications
- 23.8 Novartis AG
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Development
- 23.8.5 Certifications
- 23.9 Pfizer Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Development
- 23.9.5 Certifications
- 23.10 Assertio Holdings
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Development
- 23.10.5 Certifications
- 23.11 Pacira Biosciences Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Development
- 23.11.5 Certifications
- 23.12 Anika Therapeutics Inc.
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Company News and Development
- 23.12.5 Certifications
- 23.13 Bioventus LLC
- 23.13.1 Financial Analysis
- 23.13.2 Product Portfolio
- 23.13.3 Demographic Reach and Achievements
- 23.13.4 Company News and Development
- 23.13.5 Certifications
- 24 Osteoarthritis Therapeutics Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
